108605
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
低剂量白细胞介素 - 2 通过调节性 T 细胞扩增减轻大鼠神经性疼痛
Authors Zhao Y, Shen L , Huang Y
Received 27 June 2025
Accepted for publication 20 September 2025
Published 26 September 2025 Volume 2025:18 Pages 5011—5022
DOI https://doi.org/10.2147/JPR.S550012
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Wendy Imlach
Yifei Zhao, Le Shen, Yuguang Huang
Department of Anesthesiology, Peking Union Medical College Hospital, Beijing, 100730, People’s Republic of China
Correspondence: Le Shen, Email pumchshenle@163.com
Background: Neuropathic pain (NP) involves complex neuroimmune interactions. Regulatory T cells (Tregs) have been implicated in immune homeostasis, but their role in NP pathogenesis and therapeutic potential remains poorly understood.
Aim: This study aimed to investigate the immunomodulatory effects of low-dose interleukin-2 (IL-2) on Treg populations and neuropathic pain behavior in a rat model of chronic constriction injury (CCI).
Methods: CCI was induced in Sprague-Dawley rats, followed by daily intraperitoneal administration of low-dose IL-2 (5000 U/day) for three consecutive days, administered either three days prior to or following CCI. Pain behaviors were assessed by measuring mechanical withdrawal threshold and thermal withdrawal latency. Treg and T conventional (Tconv) cell subsets were quantified by flow cytometry in blood, spleen, dorsal root ganglia (DRG), and spinal cord. Functional markers (CD62L, ICOS) and serum IL-10 concentrations were also examined.
Results: CCI increased T cell infiltration in the DRG, with limited endogenous Treg expansion. Low-dose IL-2 significantly elevated Treg proportions in blood, spleen, and DRG, without promoting Tconv expansion. In the DRG, IL-2–treated CCI rats showed a marked increase in Treg proportions, peaking at day 3 (20.73 ± 2.83% vs 6.74 ± 0.67% in controls) and remaining significantly elevated through day 21. IL-2 also enhanced Treg expression of ICOS and CD62L and increased serum IL-10 levels. Rats receiving IL-2 treatment demonstrated significant improvements in mechanical pain thresholds (61.53 ± 8.46% reduction) and thermal pain thresholds (52.74 ± 6.73% reduction) relative to controls on day 21. Preventive IL-2 injection (pre-CCI) was less effective than post-CCI administration.
Conclusion: Low-dose IL-2 selectively augments functional Tregs and mitigates neuropathic pain through modulation of peripheral and neural immune responses. Further Treg-specific mechanistic validations are required to confirm its potential for translational clinical therapy.
Keywords: interleukin-2, regulatory T cells, neuropathic pain, chronic constriction injury, neuro-immune crosstalk
Department of Anesthesiology, Peking Union Medical College Hospital, Beijing, 100730, People’s Republic of China
Correspondence: Le Shen, Email pumchshenle@163.com
Background: Neuropathic pain (NP) involves complex neuroimmune interactions. Regulatory T cells (Tregs) have been implicated in immune homeostasis, but their role in NP pathogenesis and therapeutic potential remains poorly understood.
Aim: This study aimed to investigate the immunomodulatory effects of low-dose interleukin-2 (IL-2) on Treg populations and neuropathic pain behavior in a rat model of chronic constriction injury (CCI).
Methods: CCI was induced in Sprague-Dawley rats, followed by daily intraperitoneal administration of low-dose IL-2 (5000 U/day) for three consecutive days, administered either three days prior to or following CCI. Pain behaviors were assessed by measuring mechanical withdrawal threshold and thermal withdrawal latency. Treg and T conventional (Tconv) cell subsets were quantified by flow cytometry in blood, spleen, dorsal root ganglia (DRG), and spinal cord. Functional markers (CD62L, ICOS) and serum IL-10 concentrations were also examined.
Results: CCI increased T cell infiltration in the DRG, with limited endogenous Treg expansion. Low-dose IL-2 significantly elevated Treg proportions in blood, spleen, and DRG, without promoting Tconv expansion. In the DRG, IL-2–treated CCI rats showed a marked increase in Treg proportions, peaking at day 3 (20.73 ± 2.83% vs 6.74 ± 0.67% in controls) and remaining significantly elevated through day 21. IL-2 also enhanced Treg expression of ICOS and CD62L and increased serum IL-10 levels. Rats receiving IL-2 treatment demonstrated significant improvements in mechanical pain thresholds (61.53 ± 8.46% reduction) and thermal pain thresholds (52.74 ± 6.73% reduction) relative to controls on day 21. Preventive IL-2 injection (pre-CCI) was less effective than post-CCI administration.
Conclusion: Low-dose IL-2 selectively augments functional Tregs and mitigates neuropathic pain through modulation of peripheral and neural immune responses. Further Treg-specific mechanistic validations are required to confirm its potential for translational clinical therapy.
Keywords: interleukin-2, regulatory T cells, neuropathic pain, chronic constriction injury, neuro-immune crosstalk